All In Biotech

Drug Trial Radar · NCT00118898

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

A Phase IIIB, Randomized Trial of Open-Label Efavirenz or Atazanavir With Ritonavir in Combination With Double-Blind Comparison of Emtricitabine/Tenofovir or Abacavir/Lamivudine in Antiretroviral-Naive Subjects

Last checked: Nov 20, 2026Latest source record: Oct 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,864 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,864

Actual

Start

Sep 2005

Primary completion

Nov 2009

Study completion Nov 2009

Sponsor

Sponsor type
Research network
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
First posted
Jul 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Currently, the preferred anti-HIV regimens used in the United States consist of two nucleoside reverse transcriptase inhibitors (NRTIs) and the nonnucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (EFV). However, with new anti-HIV drugs being approved, alternative regimens need to be tested to determine if new drug combinations have increased effectiveness in treating HIV. The purpose of this study is to test the safety, tolerability, and effectiveness of four different regimens in HIV-infected adults who have never taken anti-HIV drugs.

Conditions

  • HIV Infections

Interventions

  • Abacavir/LamivudineDrug

    600 mg abacavir/300 mg lamivudine tablet taken orally daily

  • AtazanavirDrug

    300 mg tablet taken orally daily

  • EfavirenzDrug

    600 mg tablet taken orally daily

  • Emtricitabine/Tenofovir disoproxil fumarateDrug

    200 mg emtricitabine/300 mg tenofovir disoproxil fumarate tablet taken orally daily

  • RitonavirDrug

    100 mg tablet taken orally daily

  • Abacavir/Lamivudine placeboDrug

    Placebo tablet taken orally daily

  • Emtricitabine/Tenofovir disoproxil fumarate placeboDrug

    Placebo tablet taken orally daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time From Randomization to Virologic FailureTime frame: Follow-up time was variable,median follow-up was 138 weeks; see 'Amount of study follow-up' outcome for details
  2. Time From Treatment Dispensation to a Grade 3/4 Safety EventTime frame: All follow-up while on initially assigned regimen; the median (25th, 75th percentile) follow-up while on initial regimen was 120 (54, 156) weeks and the range was 0 to 205 weeks.
  3. Time From Treatment Dispensation to Treatment ModificationTime frame: Follow-up time was variable,median follow-up was 138 weeks; see 'Amount of study follow-up' outcome for details

Locations

52 sites in 2 countries. Site status is shown where the registry gives one.

  • Usc Crs (1201)

    Los Angeles, California

  • UCLA CARE Center CRS (601)

    Los Angeles, California

  • Stanford CRS (501)

    Palo Alto, California

  • Ucsd, Avrc Crs (701)

    San Diego, California

  • Ucsf Aids Crs (801)

    San Francisco, California

  • San Mateo County AIDS Program (505)

    Stanford, California

  • Willow Clinic (507)

    Stanford, California

  • Harbor-UCLA Med. Ctr. CRS (603)

    Torrance, California

  • University of Colorado Hospital CRS (6101)

    Aurora, Colorado

  • Georgetown University CRS (GU CRS) (1008)

    Washington D.C., District of Columbia

  • University of Miami AIDS CRS (901)

    Miami, Florida

  • Emory University

    Atlanta, Georgia

  • The Ponce de Leon Center CRS (5802)

    Atlanta, Georgia

  • Northwestern University CRS (2701)

    Chicago, Illinois

  • Cook County Hospital Core Center (2705)

    Chicago, Illinois

  • Rush Univ. Med. Ctr. ACTG CRS (2702)

    Chicago, Illinois

  • Indiana University Hospital (2601)

    Indianapolis, Indiana

  • Wishard Hospital (2603)

    Indianapolis, Indiana

  • Univ of Iowa Hosp and Clinic (1504)

    Iowa City, Iowa

  • IHV Baltimore Treatment CRS (4651)

    Baltimore, Maryland

  • Johns Hopkins Adult AIDS CRS (201)

    Baltimore, Maryland

  • Massachusetts General Hospital ACTG CRS (101)

    Boston, Massachusetts

  • Brigham and Women's Hosp. ACTG CRS (107)

    Boston, Massachusetts

  • Bmc Actg Crs (104)

    Boston, Massachusetts

  • Beth Israel Deaconess Med. Ctr., ACTG CRS (103)

    Boston, Massachusetts

  • Washington U CRS (2101)

    St Louis, Missouri

  • SUNY - Buffalo (Rochester) (1102)

    Buffalo, New York

  • Cornell CRS (7804)

    New York, New York

  • Weill Med. College of Cornell Univ., The Cornell CTU -Chelsea (7803)

    New York, New York

  • NY Univ. HIV/AIDS CRS (401)

    New York, New York

  • HIV Prevention & Treatment CRS (30329)

    New York, New York

  • Harlem ACTG CRS (31483)

    New York, New York

  • AIDS Community Health Ctr. ACTG CRS (1108)

    Rochester, New York

  • University of Rochester ACTG CRS (1101)

    Rochester, New York

  • Unc Aids Crs (3201)

    Chapel Hill, North Carolina

  • Wake County Department of Health (30076)

    Chapel Hill, North Carolina

  • Duke University Medical Center Adult CRS (1601)

    Durham, North Carolina

  • Moses H. Cone Memorial Hospital CRS (3203)

    Greensboro, North Carolina

  • University of Cincinnati CRS (2401)

    Cincinnati, Ohio

  • Case CRS (2501)

    Cleveland, Ohio

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.